Figure 1.
Response outcomes of epcoritamab vs comparators. Unadjusted and adjusted ORR and CR rates with ORs (95% CI) for (A) epcoritamab vs SOC/CIT; (B) epcoritamab vs mosunetuzumab; and (C) epcoritamab vs odronextamab.
Response outcomes of epcoritamab vs comparators. Unadjusted and adjusted ORR and CR rates with ORs (95% CI) for (A) epcoritamab vs SOC/CIT; (B) epcoritamab vs mosunetuzumab; and (C) epcoritamab vs odronextamab.
